96 results on '"Colice, Gene"'
Search Results
2. Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma (NAVIGATOR)
3. Effect of tezepelumab on healthcare utilization in patients with severe, uncontrolled asthma: the NAVIGATOR study
4. Efficacy and safety of tezepelumab in patients with uncontrolled disease while receiving maintenance therapy for moderate or severe asthma
5. Effect Of Tezepelumab In Patients With Severe, Uncontrolled Asthma By Age Of Onset, Allergic Status, And Eosinophilic Phenotype
6. Efficacy Of Tezepelumab In Patients With Severe, Uncontrolled Asthma By Specific Perennial Allergen Immunoglobulin E Thresholds
7. Tezepelumab Efficacy By SNOT-22 Score In Patients With Severe, Uncontrolled Asthma And Comorbid Nasal Polyps In NAVIGATOR
8. Tezepelumab Reduces Exacerbations Across All Seasons In Patients With Severe, Uncontrolled Asthma With Seasonal Allergy: Results From The Phase 3 NAVIGATOR Study
9. Efficacy and safety of tezepelumab in patients recruited in Japan who participated in the phase 3 NAVIGATOR study
10. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study
11. Feno differentiates epithelial gene expression clusters: Exploratory analysis from the MESOS randomized controlled trial
12. EFFICACY OF TEZEPELUMAB IN PATIENTS WITH UNCONTROLLED ASTHMA DESPITE RECEIVING TREATMENT FOR MODERATE OR SEVERE DISEASE: POOLED ANALYSIS OF PATHWAY AND NAVIGATOR STUDIES
13. EFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA GROUPED BY NUMBER OF ADDITIONAL ASTHMA CONTROLLER MEDICATIONS: RESULTS FROM THE PHASE 3 NAVIGATOR STUDY
14. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study
15. Tezepelumab Reduces Inflammatory Biomarkers as Early as Week 2 and Maintains Reductions Until Week 52 in the Phase 3 NAVIGATOR Severe Asthma Trial
16. Efficacy of Tezepelumab in Patients with Moderate-to-Severe, Uncontrolled Asthma: A Pooled Analysis of the Phase 2b PATHWAY and Phase 3 NAVIGATOR Studies
17. Tezepelumab Reduces Exacerbations Across All Seasons in Patients with Severe, Uncontrolled Asthma: Results from the Phase 3 NAVIGATOR Study
18. Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma with Respiratory Comorbidities: Results from the Phase 3 NAVIGATOR Study
19. Tezepelumab normalizes serum interleukin-5 and -13 levels in patients with severe, uncontrolled asthma
20. Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma and Perennial Allergy
21. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial
22. EFFECT OF TEZEPELUMAB ON LUNG FUNCTION IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA IN THE PHASE 3 NAVIGATOR STUDY
23. EFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA GROUPED BY BASELINE BMI IN THE NAVIGATOR STUDY
24. Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma: Results from the Phase 3 NAVIGATOR Study
25. Tezepelumab Efficacy in Patients with Allergic and Non-Allergic Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b Study
26. Treatment with Tezepelumab Reduces Serum Interleukin (IL)-5 and IL-13 in Patients with Severe, Uncontrolled Asthma to Levels Approaching those Observed in Healthy Individuals
27. Tezepelumab Pharmacokinetics, Safety, and Tolerability After Administration via Vial-and-syringe, Accessorized Prefilled Syringe, or Autoinjector: A Randomized Trial in Healthy Volunteers
28. THE EFFECT OF TEZEPELUMAB ON EXACERBATIONS IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA ACCORDING TO BASELINE INHALED CORTICOSTEROID DOSE: RESULTS FROM THE PHASE 2B PATHWAY STUDY
29. Effect of Tezepelumab on Exacerbations in Patients with Severe, Uncontrolled Asthma, According to Baseline Body Mass Index: Results from the Phase 2b PATHWAY Study
30. Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials
31. Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial
32. Real-Life Outcomes for Patients with Asthma Prescribed Spacers for Use with Either Extrafine- or Fine-Particle Inhaled Corticosteroids
33. Inhaled Corticosteroid Adherence Patterns in a Longitudinal Asthma Cohort
34. Reply
35. Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma
36. Small-particle Inhaled Corticosteroid as First-line or Step-up Controller Therapy in Childhood Asthma
37. Response
38. A simple rule to identify patients with chronic obstructive pulmonary disease who may need treatment reevaluation
39. Counterpoint: Should Fibrinolytics Be Routinely Administered Intrapleurally for Management of a Complicated Parapneumonic Effusion? No
40. Rebuttal From Drs Colice and Idell
41. Asthma outcomes and costs of therapy with extrafine beclomethasone and fluticasone
42. Comparative Effectiveness of Extrafine Hydrofluoroalkane Beclometasone (EF HFA-BDP) and Fluticasone Propionate (FP) in Smoking Asthmatic Patients — a Retrospective, Real-Life Observational Study in a UK Primary Care Asthma Population
43. Treatment With Formoterol Fumarate Inhalation Solution (FFIS) Among COPD Patients With High Use of Nebulized Short Acting Beta 2-Agonists (SABAs
44. Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma
45. The CHOICE survey: high rates of persistent and uncontrolled asthma in the United States
46. Reply
47. Prescribing practices and asthma control with hydrofluoroalkane-beclomethasone and fluticasone: A real-world observational study
48. Section 2. Exercise-Induced Bronchospasm: Albuterol versus Montelukast
49. New-onset mild asthma III: A sequel to 2 “Oscar winners”
50. Particle size of inhaled corticosteroids: Does it matter?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.